Pierre Fabre announces the deployment of Kalabie ELN to support its R&D Dermo-Cosmetics projects since May 2006

Paris, France (September 6, 2006), The Guepard project is based on the Kalabie ELN (Electronic Laboratory Notebook) platform developed and marketed by Klee Group. This application, used daily by 120 users, makes it possible to manage all task requests for the R&D department of Pierre Fabre Dermo Cosmetic.

 

“In addition, Guepard provides global project progress indicators, history (events on the

project), associated references and participants. This enables a first level analysis in terms of workload and better distribution of tasks and refined reporting. The result is more precise piloting of the R & D activity” indicates Jean-Philippe Ourgaud, User Project Leader within R&D Dermo-Cosmetics Management.

 

“Guepard is a major step in improving the productivity of the R & D by means of informatics tools. The application makes it possible to coordinate complex activities at the operational level and provides insights for management”, states Thierry Adenis Head of R&D IS. “The success of this major project for our R&D activity results from the efficient collaboration between all actors (IS department, users, Klee) which made it possible to maintain project commitments in terms of schedule, cost and quality” adds Samuel Mercier IS Senior Project Manager for R&D.

 

“This successful deployment, clearly demonstrates the capacity of Kalabie ELN to support e-R&D solutions for the Life Science industry. Combining Process Management, Knowledge Management and IP protection into a single solution brings a unique value to the marketplace.” declares Alain Meller Associate Director at Klee Group and in charge of the Kalabie department.

 

About Pierre Fabre

The Pierre Fabre Group employs over 9,000 people and is present in the ethical drugs, family medication and dermo-cosmetic care sectors with brands such as Avène, Ducray, A-Derma, Galénic, Klorane and René Furterer. The Group generates 44% of its activity from international markets. With over 1000 researchers, Pierre Fabre Médicament dedicates 23 % of its sales to R&D, notably in five main therapeutic areas, decisive for public health: Cancer therapy, Central Nervous System, Cardiology, Internal Medicine/Urology and Dermatology. More information can be found at http://www.pierre-fabre.com/

 

About Kalabie and Klee Group

Kalabie ELN developed and marketed by Klee Group is a packaged software solution for the Life Science sector where Klee is present since 1989. Klee Group is both a software editor and a provider of turn key IT solutions involving both bespoke development and system integration for large to medium accounts in Europe. Kalabie ELN is a powerful Electronic Laboratory Notebook solution that has been applied to various domains and has been running in production at major Pharmaceuticals companies since 2002.  More information can be found at http://www.kalabie.com.